| Lupus Nephritis |
ChiCTR-TRC-10001052: Effect of wuzhi capsule on blood concentration of mycophenolate mofetil in patients of chronic glomerulonephritis |
|
|
| Completed | 4 | 40 | | mycophenolate mofetil 500mg bid，Adjust the drug dose according to the blood concentration of mycophenolate mofetil but no use of wuzhi capsule ;mycophenolate mofetil 250mg bid, adding wuzhi capsule according to the blood concentration of mycophenolate mofetil | Nephrology Department of West China Hospital; Level of the institution：, Nephrology Department of West China Hospital | chronic glomerulonephritis | | | | |
ChiCTR-TNRC-10000960: Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranousproliferative lupus nephritis: prospective cohort study |
|
|
| Completed | 4 | 40 | | Tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months ;cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day) for 6 months | the First Affiliated Hospital, College of Medicine, Zhejiang University; Level of the institution：, Self-funding | lupus nephritis | | | | |
ChiCTR-TRC-10000931: Treatment of severe Lupus Nephritis with Tacrolimus (FK 506) based immunosuppression |
|
|
| Completed | 4 | 20 | | Tactrolimus administrated orally ;CTX administrated intravenousely | Shanghai Changzheng Hospital; Astellas Pharma China, Inc., Astellas Pharma China, Inc. | Severe Lupus Nephritis (Class III, IV, V+III, V+IV) | | | | |
ChiCTR-TRC-09000587: The intensive therapy of severe lupus nephritis: a multicenter, randomized, controlled prospective clinical trial. |
|
|
| Completed | 4 | 360 | | NIH standard program (Induction period, follow-up once every four weeks; consolidation therapy: follow-up once every twelve weeks, maintaince therapy: follow-up once every twelve weeks ;Intensive group: mini-pulse of cyclophosphamid, hydroxycholoquin and another immunosupressive agent, such as mycophenolate, leflunomide, azathioprine or Methotrexate) | The department of Rheumotology and Immunology, People’s Hospital, Peking University.; People’s Hospital, Peking University, self supported | sever lupus nephritis | | | | |
| Recruiting | 4 | 120 | | MMF 0.75~1.0g/d in induction stage, MMF0.5~0.75g/d in maintenance stage ;FK506 0.1mg/kg/d in induction stage, FK506 0.05mg/kg/d in maintenance stage ;Intravenous CYC was given in monthly pulses of 0.5-0.75g/m2 in induction stage, Aza 1-2mg/kg/d in maintenance stage | Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China; Level of the institution：, Self-financing | Active lupus nephritis | | | | |
ChiCTR-TRC-13003612: A Clinical Study of the Efficacy and Safety of Shenyankangfu Tablets in the Treatment of Primary Glomerulonephritis and Diabetic Kidney Disease |
|
|
| Suspended | 4 | 720 | | shenyankangfu tablets + Losartan potassium tablets mimetic agent×2 ;shenyankangfu tablets mimetic agent +losartan potassium tablets 50mg +losartan potassium tablets mimetic agent ;shenyankangfu tablets mimetic agent +losartan potassium tablets 50mg×2 ;shenyankangfu tablets + Losartan potassium tablets 50mg+ losartan potassium tablets mimetic agent ;shenyankangfu tablets +losartan potassium tablets 50mg×2 | Chinese PLA General Hospital; Tianjin TongRenTang Group Co., Ltd., Enterprise Support | Primary Glomerulonephritis and Diabetic Kidney Disease | | | | |
| Completed | 4 | 60 | | Basal immunotherapy and hydroxychloroquine ;Basal immunotherapy | the Affiliated Hospital of Guangdong Medical College; Level of the institution：, Self support | Systemiclupuserythematosus Lupusnephritis | | | | |
2017-001619-35: Rituximab as first-line therapy in lupus nephritis Rituximab en première ligne thérapeutique dans la néphrite lupique |
|
|
| Ongoing | 4 | 5 | Europe | Solution for injection/infusion, Mabthera | Cliniques Universitaires Saint-lus, Université catholique de Louvain, Cliniques Universitaires saint-Luc, Université catholique de Louvain | Lupus Nephritis Néphrite Lupique, Lupus Nephritis Néphrite Lupique, Diseases [C] - Immune System Diseases [C20] | | | | |
| Not yet recruiting | 4 | 2400 | | Zhenqi Yishen Keli | Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine; Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Self-raised | Chronic glomerulonephritis | | | | |
ChiCTR1800017190: A multi-center, controlled, randomized, open-label clinical study on the efficacy and safety of Kunxian Capsule in the treatment of partially relieved lupus nephritis |
|
|
| Recruiting | 4 | 172 | | Kunxian Capsule (0.6g bid po) + Glucocorticoid (equal to less than 10mg/d prednisone) ;Mycophenloate Mofetil Tablets (0.5g bid po) + Glucocorticoid (equal to less than 10mg/d prednisone) | Department of rheumatology, Guangdong Provincial Hospital of Chinese Medicine; Guangzhou Baiyunshan Chenliji Pharmaceutical Company Limited, Guangzhou Baiyunshan Chenliji Pharmaceutical Company Limited | Lupus nephritis | | | | |
ChiCTR2000031731: Effcacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis: a Multicenter Randomized Controlled Clinical Trial |
|
|
| Not yet recruiting | 4 | 332 | | basic treatment combined with Jinshuibao ;basic treatment and placebo | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Jiangxi Jinshuibao Pharmaceutical Co. Ltd. | Chronic Kidney Disease | | | | |
AURORA, NCT03214731: Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis |
|
|
| Recruiting | 4 | 90 | RoW | Artesunate, Art, placebo | Sun Yat-sen University, The First People's Hospital of Yunnan, The First Affiliated Hospital of Nanchang University, General Hospital of Ningxia Medical University, First Affiliated Hospital of Fujian Medical University, Shenzhen Second People's Hospital, The Third Xiangya Hospital of Central South University, Tongji Hospital | Lupus Nephritis | 09/22 | 09/22 | | |
NCT05748925: Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | dapagliflozin, placebo | Mansoura University | SLE, Lupus Nephritis, SGLT2 Inhibitors | 10/23 | 12/23 | | |
NCT05704088: SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Dapagliflozin tablet, placebo | Mansoura University | SGLT2 INHIBITORS, Lupus Nephritis, BMD | 10/23 | 12/23 | | |
FACT, NCT05546047: A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients |
|
|
| Active, not recruiting | 4 | 34 | US | Acthar Gel 80 UNT/ML Injectable Solution, Tacrolimus 1.0 mg | NephroNet, Inc., Mallinckrodt | Fibrillary Glomerulonephritis | 10/23 | 10/24 | | |
| Recruiting | 4 | 200 | RoW | GlucoCorticoid, Rituximab, Cyclophosphamide | Wang Mo | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis | 12/23 | 12/25 | | |
| Completed | 4 | 8 | US | CellCept, Mycophenolate Mofetil, ACTHar gel, ACTHar, H.P. ACTHar Gel, Repository corticotropin | Columbia University | Lupus Nephritis | 01/24 | 01/24 | | |
CLIgAN, NCT04662723: Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. |
|
|
| Recruiting | 4 | 878 | Europe | Corticosteroid, Methylprednisolone succinate, prednisolone, Renin-angiotensin sytem blockers, Ramipril, lisinopril, losartan, Sodium-glucose cotransporter 2 inhibitor, dapagliflozin, canagliflozin, empagliflozin | Fondazione Schena, University of Bari | Glomerulonephritis, Immunoglobulin A Nephropathy | 06/24 | 12/26 | | |
NCT02630628: Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis |
|
|
| Active, not recruiting | 4 | 130 | RoW | Tacrolimus, Prograf, Mycophenolate mofetil, Cellcept | The University of Hong Kong | Lupus Nephritis | 01/25 | 01/25 | | |
ChiCTR2200064053: A real world study of the efficacy and safety of belliumab in children with lupus nephritis |
|
|
| Not yet recruiting | 4 | 400 | | no ;no | Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University, self-funded | lupus nephritis in children | | | | |
NCT06528015: Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy |
|
|
| Not yet recruiting | 4 | 206 | RoW | probiotics combined with enteric-coated budesonide capsule, probiotics placebo combined with enteric-coated budesonide capsules | Gang Xu, China Primary Health Care Foundation | Glomerulonephritis, IGA, Probiotics, Budesonide | 12/26 | 12/28 | | |
ChiCTR2200066257: Multi-center study of Belimumab in the treatment of lupus nephritis |
|
|
| Not yet recruiting | 4 | 50 | | None | Children's Hospital of Zhejiang Univsersity; Children's hospital of Zhejiang Univsersity, No funding support | Systemic lupus erythermatosus | | | | |
| Recruiting | 4 | 224 | RoW | Cyclophosphamide, Mycophenolate Mofetil | Second Xiangya Hospital of Central South University, Peking Union Medical College Hospital, Children's Hospital of Chongqing Medical University, Beijing Children's Hospital, Jiangxi Province Children's Hospital, The Affiliated Hospital of Qingdao University, Shenzhen Children's Hospital, The First Affiliated Hospital of Zhengzhou University, The Children's Hospital of Zhejiang University School of Medicine, The Second Hospital of Hebei Medical University | Mycophenolate Mofetil, Cyclophosphamide, Lupus Nephritis | 05/25 | 05/25 | | |
NCT05933213: Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis |
|
|
| Not yet recruiting | 4 | 205 | NA | Mescaline sodium enteric-coated tablets, Morte-mescaline, Glucocorticoids | Xiangya Hospital of Central South University, Beijing Medical Award Foundation | Lupus Nephritis | 07/25 | 12/25 | | |
ChiCTR2200063739: The efficacy and safety of telitacicept and belimumab in active lupus nephritis in the real world: a prospective cohort study |
|
|
| Not yet recruiting | 4 | 60 | | ; | Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Rongchang Biopharmaceutical (Yantai) Co., Ltd. | lupus nephritis | | | | |
NCT05916781: Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus |
|
|
| Recruiting | 4 | 220 | RoW | Mycophenolate Mofetil, MMF, Tacrolimus, TAC, Glucocorticoid | Chinese SLE Treatment And Research Group, Peking Union Medical College Hospital | Systemic Lupus Erythematosus, Lupus Nephritis | 07/25 | 07/26 | | |
ChiCTR2100050955: A single-arm, single-center clinical study of rituximab therapy in AAGN-induced remission |
|
|
| Recruiting | 4 | 20 | | Rituximab therapy during induction of AAGN | Pediatric Hospital Affiliated to Fudan University; Pediatric Hospital Affiliated to Fudan University, Self-funded | ANCA-associated glomerulonephritis | | | | |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
ChiCTR2400086506: Studies on PK/PD variability and individualized administration of mycophenolic acid in patients with lupus nephritis based on a population-based approach |
|
|
| Not yet recruiting | 4 | 60 | | None; None | Guizhou Provincial People’s Hospital; Guizhou Provincial People’s Hospital, National Natural Science Foundation of China | lupus nephritis | | | | |
| Recruiting | 4 | 30 | Europe | Rituximab, Mycophenolate Mofetil, Cyclophosphamide, Corticosteroids | Institutul Clinic Fundeni | Lupus Nephritis | 12/28 | 12/28 | | |
2020-005835-60: Treatment of lupus nephropathy without the addition of oral corticosteroids: a study comparing conventional corticosteroid and Mycophenolate Mofetil (MMF) therapy with Obinutuzumab and MMF Traitement des néphropathies lupiques sans adjonction de corticoïdes par voie orale: étude comparant un traitement classique par corticoïdes et Mycophénolate Mofétil (MMF) à un traitement par l’Obinutuzumab et le MMF |
|
|
| Not yet recruiting | 3 | 196 | Europe | Obinutuzumab, PREDNISONE, Mycophenolate mofetil, Azathioprine, RO5072759, Concentrate for solution for infusion, Tablet, , Gazyvaro | Assistance Publique – Hôpitaux de Paris (AP-HP), ministère de la santé, Roche | The study population will consist of Children (14 years and above) and adults (until 75 years old) with lupus nephritis ISN/RPS class III or IV (A or A/C) ± V with active lesions in at least 10% of the viable glomeruli, AND urine protein-to-creatinine ratio (uPCR) ≥ 0.5 g/g. La population étudiée sera composée d'enfants (à partir de 14 ans) et d'adultes (jusqu'à 75 ans) présentant un lupus néphrétique ISN/RPS de classe III ou IV (A ou A/C) ± V avec des lésions actives dans au moins 10 % des glomérules viables, ET un rapport protéines/créatinine urinaire (uPCR) ≥ 0,5 g/g., Children (14 years and above) and adults (until 75 years old) with lupus nephritis Enfants (à partir de 14 ans) et adultes (jusqu'à 75 ans) atteints de lupus néphrétique, Body processes [G] - Immune system processes [G12] | | | | |
| Recruiting | 3 | 32 | | | Royal Brisbane, Royal Brisbane Hospital research Foundation, Novartis Pharmaceuticals Australia | Lupus Nephritis patients | | | | |
2020-003767-25: A Phase 3 study to Evaluate the Efficacy and Safety of Pegcetacoplan administered subcutaneously in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
|
|
| Ongoing | 3 | 100 | Europe, RoW | Pegcetacoplan, APL-2, Solution for injection/infusion | Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc. | complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN), Rare kidney disease which can reoccur after a kidney transplant., Diseases [C] - Immune System Diseases [C20] | | | | |
2018-004611-50: The Use of Rituximab IN treatment of immune-mediated Glomerulonephritis (TURING) |
|
|
| Not yet recruiting | 3 | 112 | Europe | Rituximab, Concentrate for solution for infusion | Cambridge University Hospitals NHS Foundation Trust, NIHR HTA | Minimal Change Disease (MCD) and Focal segmental glomerulosclerosis (FSGS), These are auto-immune renal diseases that present with a common clinical phenotype, the nephrotic syndrome (NS). | | | | |
| Active, not recruiting | 3 | 100 | Europe | mycophenolate mofetil or azathioprine, immunosuppressive treatment discontinuation | Assistance Publique Hopitaux De Marseille | Nephritis of Lupus | 01/21 | 08/21 | | |
2021-006647-99: Efficacy of Desmopressin in safaty outcomes post kindey biopsy |
|
|
| Not yet recruiting | 3 | 424 | Europe | Infusion, Minirin (4 mcg/ml) | Medical University of Bialystok, Agencja Badań Medycznych | Rare and ultra-rare glomerulonephritis, Rare and ultra-rare glomerulonephritis, Not possible to specify | | | | |
2020-005830-14: Study of safety, efficacy and tolerability of ianalumab versus placebo, in combination with SOC therapy, in participants with active lupus nephritis Randomizált, kettős vak, párhuzamos csoportos, placebo kontrollos,multicentrikus, III. fázisú vizsgálat a hagyományos kezelés mellett alkalmazott ianalumab hatásosságának, biztonságosságának és tolerálhatóságának értékelésére aktív lupus nephritisben szenvedő résztvevők körében (SIRIUS-LN) |
|
|
| Ongoing | 3 | 420 | Europe, RoW | ianalumab, VAY736, Solution for injection in pre-filled syringe | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Lupus nephritis, Inflammation of the kidneys that is a severe complication of systemic lupus, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-005772-19: An extension clinical trial of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis Un estudio de extensión de secukinumab subcutáneo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo en pacientes con nefritis lúpica activa. |
|
|
| Ongoing | 3 | 310 | Europe, RoW | Solution for injection in pre-filled syringe, Cosentyx | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Lupus Nephritis Nefritis lúpica, Lupus Nephritis is an inflammation of kidneys caused by systemic lupuserythematosus, an autoimmune disease (body's immune system targetsits own body tissues) that can affect any part of the body. Nefritis lúpica:inflamación de los riñones causada por lupus eritematoso sistémico,enfermedad autoinmune (el sistema inmune ataca a los tejidos propios) que puede afectar a cualquier parte del cuerpo, Diseases [C] - Immune System Diseases [C20] | | | | |
2022-000257-83: A large global research study for an investigational drug called atacicept is being tested for the treatment of active lupus nephritis in a randomized manner, and is a placebo-controlled, double-blind study. Placebo-controlled provides a way to measure the actual effect of the investigational drug (atacicept). Double-blind means that the patient and the study doctor will not know if the patient is getting atacicept or placebo. |
|
|
| Not yet recruiting | 3 | 290 | Europe | Atacicept, VT-001, Solution for injection in pre-filled syringe | Vera Therapeutics, Inc., Vera Therapeutics, Inc. | patients with lupus nephritis sujetos con nefritis lúpica, Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease; a disorder in which the body's immune system attacks the body's own cells and organs., Body processes [G] - Immune system processes [G12] | | | | |
2021-006544-26: Lupus nephritis with rituximab and no maintainance therapy Rituximab per la gestione della nefrite lupica senza necessità di terapia cronica |
|
|
| Not yet recruiting | 3 | 54 | Europe | Rixathon, MICOFENOLATO MOFETILE, Endoxan, [045450032], [045833011], [015628086], Concentrate for solution for injection/infusion, Tablet, Lyophilisate for solution for infusion, MICOFENOLATO MOFETILE, Endoxan | A.S.L. TO 2, Fondazione CMID | lupus nephritis Nefrite Lupica, renal inflammation in subjects with lupus infiammazione renale in corso di lupus, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05432531: Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis |
|
|
| Active, not recruiting | 3 | 60 | RoW | Anti JAK1,2, Baritava, Cyclophosphamid, Indoxan | Assiut University | Lupus Nephritis | 12/22 | 04/23 | | |
2022-002833-33: A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Un estudio para evaluar la seguridad y la eficacia a largo plazo de pegcetacoplán en participantes con glomerulopatía C3 o glomerulonefritis membranoproliferativa por inmunocomplejos |
|
|
| Ongoing | 3 | 100 | Europe, RoW | Pegcetacoplan, APL-2, Solution for injection/infusion, Aspaveli | Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc | C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) Glomerulopatía por C3 (GC3) o glomerulonefritis membranoproliferativa por inmunocomplejos (GNMP-IC), Rare kidney disease which can reoccur after a kidney transplant. Enfermedad renal rara que puede reaparecer después de un trasplante de rinón, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05232864 / 2021-005772-19: Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis |
|
|
| Terminated | 3 | 31 | Europe, Japan, RoW | Secukinumab, AIN457 | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 08/23 | 08/23 | | |
| Terminated | 3 | 275 | Europe, Canada, Japan, US, RoW | secukinumab, AIN457 | Novartis Pharmaceuticals | Lupus Nephritis | 09/23 | 09/23 | | |
NCT06406205: A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis |
|
|
| Recruiting | 3 | 270 | RoW | Voclosporin（QL1074）, Placebo | Qilu Pharmaceutical Co., Ltd. | Lupus Nephritis | 06/27 | 06/28 | | |
BEAM, NCT05863936: Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis |
|
|
| Recruiting | 3 | 15 | RoW | Methylprednisolone Injectable Suspension, Methylprednisolone pulse therapy, Belimumab Injection, Beliumab induction therapy, Immunosuppressive Agents, Multi-target immunosuppressive therapy | Nanjing University School of Medicine | Lupus Nephritis, Remission, Safety Issues | 03/24 | 12/24 | | |
VALIANT, NCT05067127: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
|
|
| Active, not recruiting | 3 | 90 | Europe, Canada, Japan, US, RoW | Pegcetacoplan, Placebo | Apellis Pharmaceuticals, Inc. | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 252 | Europe, US, RoW | Obinutuzumab, Gazyva, GA101, RO5072759, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine | Hoffmann-La Roche | Lupus Nephritis | 08/24 | 02/29 | | |
|
| Recruiting | 3 | 183 | Europe, Canada, Japan, US, RoW | LNP023, iptacopan | Novartis Pharmaceuticals, Novartis Pharma AG | C3 Glomerulopathy, Idiopathic Immune-complex-membranoproliferative Glomerulonephritis | 10/24 | 12/28 | | |
| Recruiting | 3 | 40 | US | Voclosporin, Placebo Oral Capsule | Aurinia Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc. | Adolescent Lupus Nephritis | 12/24 | 01/25 | | |
NCT05631717: The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN |
|
|
| Recruiting | 3 | 40 | RoW | Human umbilical cord mesenchymal stem cells, Interleukin-2, Recombinant Human Interleukin-2(1) for Injection | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus, Lupus Nephritis | 06/25 | 12/25 | | |
NCT05510323: Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD |
|
|
| Recruiting | 3 | 208 | RoW | Prednisolone, Prednisolone plus Cyclophosphamide | Air Force Military Medical University, China | Glomerulonephritis, IGA | 08/25 | 08/28 | | |
RENATO, NCT05946564: A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - Trial |
|
|
| Recruiting | 3 | 126 | Europe | Pioglitazone (ACTOS®), Placebo of Pioglitazone | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France | ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis | 04/27 | 10/27 | | |
| Suspended | 3 | 360 | Europe, US | Atacicept, VT-001, Placebo | Vera Therapeutics, Inc. | Lupus Nephritis (LN) | 03/26 | 12/28 | | |
| Enrolling by invitation | 3 | 40 | NA | voclosporin | Aurinia Pharmaceuticals Inc., Labcorp Corporation of America Holdings, Inc | Adolescent Lupus Nephritis | 06/26 | 09/26 | | |
| Recruiting | 3 | 68 | Europe, Canada, Japan, US, RoW | Placebo, iptacopan | Novartis Pharmaceuticals | IC-MPGN | 10/26 | 11/26 | | |
| Recruiting | 3 | 346 | Europe, Japan, US, RoW | Anifrolumab, Medi-546, Placebo | AstraZeneca | Lupus Nephritis | 09/26 | 07/28 | | |
PRIME, NCT05914155: Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome |
|
|
| Recruiting | 3 | 88 | Japan | Rituximab (genetical recombination), Placebo | Shoichi Maruyama MD PhD | Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic | 12/26 | 12/26 | | |
| Recruiting | 3 | 420 | Europe, Canada, US, RoW | ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo | Novartis Pharmaceuticals | Lupus Nephritis | 03/27 | 07/30 | | |
VALE, NCT05809531 / 2022-002833-33: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
|
|
| Active, not recruiting | 3 | 100 | Europe, US, RoW | Pegcetacoplan, APL-2 | Apellis Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | 07/27 | 07/27 | | |
OBILUP, NCT04702256 / 2020-005835-60: Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF |
|
|
| Recruiting | 3 | 196 | Europe | Obinutuzumab administration, GAZYVARO® administration, Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil, Corticosteroid Series, Administration of methylprednisolone, paracetamol and dexchlorpheniramine, Premedication | Assistance Publique - Hôpitaux de Paris, Roche Pharma AG | Lupus Nephritis, Systemic Lupus Erythematosus (SLE) | 12/31 | 12/31 | | |
ACTRN12611000778987: Evaluation of Captopril and Nifedipine in Treatment of Hypertension in Children with Post-streptoccal Acute Glomerulonephritis with Hypertension- A Randomized Control Trial |
|
|
| Recruiting | 2/3 | 40 | | | Universiti Sains Malaysia (USM), Universiti Sains Malaysia (USM) | Control of Blood Pressure in Patients with Post-sterptococcal Acute Glomerulonephritis (PSAGN), Renal profiles in patients with Post-streptococcal Acute Glomerulonephritis (PSAGN) | | | | |
NCT04892212: Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis |
|
|
| Not yet recruiting | 2/3 | 20 | NA | Sirolimus, Rapamycin | Peking Union Medical College Hospital, North China Pharmaceutical Group Corporation | Lupus Nephritis, Immunosuppression, Effect of Drug | 06/23 | 10/23 | | |
2005-003070-19: A randomized, multicenter, parallel-group, open-label study to assess the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) versus continuation of previous therapy in patients with proliferative lupus nephritis on standard maintenance therapy |
|
|
| Ongoing | 2 | 16 | Europe | Myfortic, ERL080A, Myfortic, Myfortic | Novartis Pharma Services AG | lupus nephritis ( as part of the disease \"Systemic Lupus Erythematosus\") | | | | |
| Completed | 2 | 126 | Europe, US, RoW | Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Methylprednisolone, Prednisone | Hoffmann-La Roche | Lupus Nephritis | 01/19 | 08/23 | | |
|
|
|
|
NCT03453619: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies |
|
|
| Completed | 2 | 21 | US | APL-2 | Apellis Pharmaceuticals, Inc. | IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease | 04/20 | 08/23 | | |
2020-001537-13: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 120 | Europe | Ravulizumab, ALXN1210, Concentrate for solution for infusion, Ultomiris | Alexion Pharmaceuticals, Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc. | Lupus Nephritis (LN)Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN)Immunoglobulin A Nephropathy (IgAN), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000097-29: A Phase II Randomized Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis Estudio fase II, aleatorizado y controlado paraevaluar la eficacia, seguridad y farmacocinética de obinutuzumab en pacientes adolescentes con nefritis lúpica de casle III o IV activa |
|
|
| Not yet recruiting | 2 | 30 | Europe | Obinutuzumab, mycophenolate mofetil, RO5072759, Concentrate for solution for infusion, Tablet, Gazyvaro, Myfenax | Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffman-La Roche Ltd. | Lupus Nephritis (LN) Nefritis lúpica (NL), Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). SLE is an autoimmune disease, in which the body’s immune system attacks its own healthy body tissue. La nefritis lúpica es una inflamación del riñón causada por el lupus eritematoso sistémico(LES).LES es una enfermedad autoinmune,en la que el sistema inmune del cuerpo ataca sus propios tejidos sanos, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04835883: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients |
|
|
| Recruiting | 2 | 10 | RoW | CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) | Hanyang University Seoul Hospital, Corestem, Inc., Ministry of Health & Welfare, Korea | Systemic Lupus Erythematosus | 11/21 | 01/26 | | |
2020-005568-79: A Clinical Study of Nipocalimab in Adult Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 80 | Europe | Nipocalimab, JNJ-80202135, Solution for infusion | Janssen-Cilag International NV, Janssen Research & Development, LLC | Active Lupus Nephritis, Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04924296: A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | NA | SHR-1314, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Lupus Nephritis | 12/21 | 09/22 | | |
| Terminated | 2 | 31 | Europe, Canada, RoW | Placebo, Cemdisiran, ALN-CC5 | Alnylam Pharmaceuticals | IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA | 03/22 | 06/23 | | |
2022-000243-80: LUPUS NEPHRITIS TREATMENT WITH MESENCHYMAL CELLS (MSV-allo®). TRATAMIENTO DE LA NEFRITIS LÚPICA con células mesenquimales (MSV-allo®). |
|
|
| Ongoing | 2 | 20 | Europe | Allogeneic adult mesenchymal stem cells bone marrow derived expanded in suspension, MSV®-allo, Suspension for injection | Hospital Universitario Rio Hortega, En tramite | Lupus nephritis Nefritis lúpica, Lupus nephritis Nefritis lúpica, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-002046-33: Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Az LNP023 hatásosságának és biztonságosságának vizsgálata III-IV-es, +/- V-ös osztályú, aktív lupus nephritisben szenvedő résztvevők körében |
|
|
| Ongoing | 2 | 240 | Europe | Iptacopan, Prednisone, LNP023, Capsule, hard, Capsule, hard + tablet, Prednisone | Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG | Lupus Nephritis Class III-IV, +/- V, Autoimmune disease, Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 2 | 13 | Europe, US, RoW | Pegcetacoplan | Apellis Pharmaceuticals, Inc. | C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis | 02/23 | 01/26 | | |
2018-003155-38: A Study of the Efficacy and Safety of Guselkumab in Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe, TREMFYA | Janssen-Cilag International NV, Janssen Research & Development | Active Lupus Nephritis, Active Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Terminated | 2 | 33 | Europe, US, RoW | Guselkumab Dose 1, CNTO 1959, Placebo, Guselkumab Dose 2, CNTO1959, Standard-of-care treatment | Janssen Research & Development, LLC | Lupus Nephritis | 02/23 | 02/23 | | |
ChiCTR2400081359: Clinical outcomes of abatacept in patients with refractory lupus nephritis: Phase II study |
|
|
| Completed | 2 | 17 | | Abatacept 125mg/week subcutaneously | Renji Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine, Self-financed by the researcher | lupus nephritis | | | | |
| Completed | 2 | 57 | Europe, RoW | CFZ533, Placebo | Novartis Pharmaceuticals | Lupus Nephritis | 06/23 | 06/23 | | |
|
NCT05714670: The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus Nephritis |
|
|
| Recruiting | 2 | 72 | RoW | Curcumin Oral Capsule, Turmeric | Ain Shams University | Lupus Nephritis, SLE Nephritis | 10/23 | 08/24 | | |
NCT06155604: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease |
|
|
| Not yet recruiting | 2 | 150 | RoW | Dapagliflozin 10mg Tab, Farxiga, Forxiga, Standard maintenance therapy, Cellcept, Imuran | The University of Hong Kong | Lupus Nephritis, Chronic Kidney Diseases | 11/26 | 11/26 | | |
PRUNE, NCT05101447: Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis |
|
|
| Withdrawn | 2 | 58 | NA | Mycophenolate Mofetil | Children's Hospital Medical Center, Cincinnati | Lupus Nephritis | 01/24 | 07/24 | | |
| Recruiting | 2 | 70 | Europe, US, RoW | ALXN2050, ACH-0145228 (formerly), Placebo | Alexion Pharmaceuticals, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN | 06/26 | 06/26 | | |
| Completed | 2 | 24 | Europe, RoW | MOR202 | HI-Bio | Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive | 12/23 | 12/23 | | |
| Completed | 2 | 177 | RoW | Zanubrutinib, BGB-3111, Brukinsa, Placebo | BeiGene | Lupus Nephritis | 02/24 | 08/24 | | |
NCT06209736: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN |
|
|
| Recruiting | 2 | 20 | Europe, RoW | OMS906 study drug, OMS906 | Omeros Corporation | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | 01/25 | 04/26 | | |
SANCTUARY, NCT04564339: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | Ravulizumab, Ultomiris, Placebo, Background Therapy | Alexion Pharmaceuticals, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy | 04/25 | 05/26 | | |
| Recruiting | 2 | 12 | US | Daratumumab | Mayo Clinic | Lupus Nephritis | 07/26 | 07/26 | | |
ADX-097-201, NCT06419205: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
|
|
| Not yet recruiting | 2 | 30 | NA | ADX-097 | Q32 Bio Inc. | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 12/25 | 12/25 | | |
NCT06295770: Obinutuzumab in Treatment of Fibrillary Glomerulonephritis |
|
|
| Recruiting | 2 | 20 | US | Obinutuzumab, Gazyva | Mayo Clinic | Fibrillary Glomerulonephritis | 05/26 | 05/26 | | |
| Recruiting | 2 | 20 | Europe | Mesenchymal stem cells (MSC), MSV, GMP-compliant MSC manufactured by IBGM in Valladolid, Placebo, Saline solution | Red de Terapia Celular, Hospital del Río Hortega, Hospital Clínico Universitario de Valladolid, University of Valladolid, Citospin | Lupus Nephritis, Lupus Erythematosus | 07/25 | 07/26 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 08/24 | 10/24 | | |
RESULT, NCT06500702: A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease |
|
|
| Not yet recruiting | 2 | 84 | NA | frexalimab, SAR442970, rilzabrutinib, placebo | Sanofi | Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | 12/26 | 02/28 | | |
NCT06581198: A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) |
|
|
| Recruiting | 2 | 144 | US, RoW | rapcabtagene autoleucel Regimen 1, rapcabtagene autoleucel Regimen 2, Standard of Care | Novartis Pharmaceuticals | Lupus Erythematosus, Systemic, Lupus Nephritis | 05/29 | 05/30 | | |
| Recruiting | 2 | 240 | Europe, US, RoW | Iptacopan (part 1), LNP023, Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo, LNP023 and placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 10/24 | 03/28 | | |
NCT00977977: Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy |
|
|
| Recruiting | 2 | 30 | US | Rituximab Infusion, Oral Cyclosporine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis | 12/24 | 01/25 | | |
| Recruiting | 2 | 39 | RoW | MSC treatment, Cellistem ® Lupus, Standard of Care, Standard of Care for Lupus Nephritis, Placebo, Placebo (for MSC) | Universidad de los Andes, Chile | Lupus Erythematosus, Systemic, Lupus Glomerulonephritis | 12/24 | 12/25 | | |
| Recruiting | 2 | 30 | Europe | Aliskiren, Enalapril | Region Skane | C3 Glomerulopathy, Membranoproliferative Glomerulonephritis, Complement Abnormality, Dense Deposit Disease, C3 Glomerulonephritis | 12/29 | 12/29 | | |
| Recruiting | 2 | 120 | RoW | Telitacicept 240 mg, RC18 240 mg, Telitacicept 160 mg, RC18 160 mg, Placebo | RemeGen Co., Ltd. | Lupus Nephritis | 12/25 | 01/26 | | |
SPARTAN, NCT04663204: A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy |
|
|
| Active, not recruiting | 2 | 12 | Europe | Sparsentan, RE-021 | University of Leicester, Travere Therapeutics, Inc. | Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune System Diseases | 03/25 | 03/25 | | |